Asahara T, Bauters C, Pastore C, Kearney M, Rossow S, Bunting S, Ferrara N, Symes J F, Isner J M
Department of Medicine (Cardiology), St Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA 02135, USA.
Circulation. 1995 Jun 1;91(11):2793-801. doi: 10.1161/01.cir.91.11.2793.
Most strategies designed to reduce restenosis by the use of pharmacological or biological reagents involve direct inhibition of vascular smooth muscle cell (SMC) proliferation. Alternatively, SMC proliferation might be indirectly inhibited if reendothelialization could be specifically facilitated at sites of balloon-induced arterial injury. Accordingly, we investigated the hypothesis that application of an endothelial cell (EC)-specific mitogen to a freshly denuded intimal surface could accelerate reendothelialization and thereby attenuate intimal hyperplasia.
The left carotid artery of 31 Sprague-Dawley rats was subjected to balloon injury, after which 16 rats were treated with a 30-minute incubation with 100 micrograms of vascular endothelial growth factor (VEGF), an EC-specific mitogen. Control animals (n = 15) received a 30-minute incubation with 0.9% saline. At 2 weeks after balloon injury, carotid artery reendothelialization was markedly superior in the VEGF-treated group compared with the control group (14.59 +/- 1.12 versus 7.96 +/- 0.51 mm2, P < 0.005). The extent of reendothelialization measured at 4 weeks after balloon injury remained superior for arteries treated with VEGF (18.04 +/- 0.90 mm2) versus saline (13.42 +/- 0.84 mm2, P < .005). Neointimal thickening was correspondingly attenuated to a statistically significant degree in arteries treated with VEGF versus the control group at both the 2-week and 4-week time points. Immunostaining for proliferating cell nuclear antigen (PCNA) disclosed a threefold increase in PCNA-positive cells in the neointima of control arteries versus VEGF-treated arteries at 2 weeks after injury.
Application of VEGF, an EC-specific growth regulatory molecule, may be effectively used in vivo to promote reendothelialization and thereby indirectly attenuate neointimal thickening due to SMC proliferation.
大多数旨在通过使用药理或生物试剂来减少再狭窄的策略都涉及直接抑制血管平滑肌细胞(SMC)增殖。另外,如果能在球囊诱导的动脉损伤部位特异性促进内皮再内皮化,那么SMC增殖可能会被间接抑制。因此,我们研究了这样一个假说:将内皮细胞(EC)特异性促有丝分裂原应用于新剥脱的内膜表面可以加速再内皮化,从而减轻内膜增生。
对31只Sprague-Dawley大鼠的左颈动脉进行球囊损伤,之后16只大鼠用100微克血管内皮生长因子(VEGF,一种EC特异性促有丝分裂原)孵育30分钟进行处理。对照动物(n = 15)用0.9%生理盐水孵育30分钟。球囊损伤后2周,VEGF处理组的颈动脉再内皮化明显优于对照组(14.59±1.12对7.96±0.51平方毫米,P < 0.005)。球囊损伤后4周测量的再内皮化程度,VEGF处理的动脉(18.04±0.90平方毫米)仍优于生理盐水处理组(13.42±0.84平方毫米,P < 0.005)。在2周和4周时间点,与对照组相比,VEGF处理的动脉内膜增厚相应地在统计学上显著减轻。损伤后2周,增殖细胞核抗原(PCNA)免疫染色显示,对照动脉内膜中PCNA阳性细胞数量是VEGF处理动脉的三倍。
应用VEGF,一种EC特异性生长调节分子,可在体内有效促进再内皮化,从而间接减轻因SMC增殖导致的内膜增厚。